Home Newsfeeds Goldman Sachs Maintains Sell on A.O. Smith, Raises Price Target to $55

Goldman Sachs Maintains Sell on A.O. Smith, Raises Price Target to $55

Goldman Sachs analyst Susan Maklari maintains A.O. Smith (NYSE:AOS) with a Sell and raises the price target from $46 to $55.

byBenzinga Newsdesk

January 12, 2023

1 minute read

Goldman Sachs analyst Susan Maklari maintains A.O. Smith (NYSE:AOS) with a Sell and raises the price target from $46 to $55.

Media
News

American Airlines Claims No Earnings Impact From Northeast Alliance Verdict: Report

By Akanksha Bakshi

May 26, 7:37 AM

A federal judge last week ruled that American Airlines Group (NASDAQ:AAL) and JetBlue Airways Corp (NASDAQ:JBLU) must cease their alliance, ordering the…

AAL

AI Data Centers Drive Electricity Demand: Goldman Sachs Picks 16 Stocks To Play The Trend

By Piero Cingari

April 29, 12:37 PM

Goldman Sachs predicts significant growth in US power demand due to AI data centers, leading to $50B investment in power generation by 2030.

CAT

Morgan Stanley Downgrades Airbnb to Underweight, Lowers Price Target to $80

By Benzinga Newsdesk

December 7, 5:30 AM

Morgan Stanley analyst Brian Nowak downgrades Airbnb (NASDAQ:ABNB) from Equal-Weight to Underweight and lowers the price target from $110 to $80.

ABNB

Amicus Therapeutics Provides EU Regulatory Update For AT-GAA

By Benzinga Newsdesk

November 7, 1:22 PM

Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for

FOLD

Goldman Sachs Maintains Sell on A.O. Smith, Raises Price Target to $55

Related Posts

American Airlines Claims No Earnings Impact From Northeast Alliance Verdict: Report

AI Data Centers Drive Electricity Demand: Goldman Sachs Picks 16 Stocks To Play The Trend

Morgan Stanley Downgrades Airbnb to Underweight, Lowers Price Target to $80

Amicus Therapeutics Provides EU Regulatory Update For AT-GAA